Please ensure Javascript is enabled for purposes of website accessibility U.S. Financial Professionals | Janus Henderson Investors

The great transition: demographic change in China

Jennifer James and Ales Koutny, emerging market specialists within the Global Bonds Team, interpret the data in China’s latest census, highlighting pressing economic and societal issues that will need to be addressed.

Growth? Value? Just fundamentals please…

Portfolio manager Steve Johnstone looks at the dominance of thematic market factors in determining market movements since the start of the pandemic, considering what the return of idiosyncratic risk in 2021 might mean for investors.

Growth? Value? Just fundamentals please…

Portfolio manager Steve Johnstone looks at the dominance of thematic market factors in determining market movements since the start of the pandemic, considering what the return of idiosyncratic risk in 2021 might mean for investors.

Fund Manager May Commentary – Lowland Investment Company

Laura Foll, CFA | Janus Henderson Investors

Laura Foll, co-fund manager of Lowland Investment Company, highlights the increased private equity takeover activity seen in May, the changes made to the portfolio and the encouraging trading updates from the portfolio’s holdings.

Biopharma’s targeted approach to growth

A new drug targeting a common mutation found in tumors represents a breakthrough in cancer therapy and a potential new source of growth for biopharma. Portfolio Manager Andy Acker and Research Analyst Agustin Mohedas explain how the science could benefit patients and biopharma alike.

The affordable care act lives on

The Supreme Court’s decision to uphold the legislation may finally bring an end to challenges to the law and further expand health care in the US